Veravas was founded by John Forrest, Joshua Soldo in 2017.

How much funding has Veravas raised?

Veravas has disclosed $21.7M raised across 3 rounds.

Where is Veravas headquartered?

Veravas is headquartered in Charleston, US.

Veravas

Charleston, US · Founded 2017 · Delaware corporation

Find your way into Veravas

Each arrow is one introduction. Sign up to fill in the first one.

122 people can intro you to John

Ask Christin Glorioso to introduce you to John Forrest

You →Christin · together at Longevity Global →John

19 people can intro you to Joshua

Ask Jamie Chen to introduce you to Joshua Soldo

You →Jamie · together at Beckman Coulter →Joshua

Your email: who you already know at Veravas, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Veravas team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Veravas develops the patented VeraBIND diagnostic platform that reduces interference in laboratory testing to measure hard-to-detect biomarkers, with a current application in blood-based early detection of tau pathology associated with Alzheimer's disease. It provides tests and sample pre-treatment solutions aimed at researchers and diagnostic labs for improved assay sensitivity and biomarker detection.</parameter> <parameter name="founders">[]

Biotech Digital Health Healthtech

Founders & leadership

Veravas was founded in 2017 by John Forrest and Joshua Soldo.

John Forrest Founder and Executive ChairmanJohn Forrest is Co-Founder and CEO of Veravas, which develops the VeraBIND diagnostic platform to measure biomarkers associated with neurodegenerative diseases. He has over 30 years of experience in healthcare IT and founding companies focused on diagnostic testing and healthcare information access.

Joshua Soldo Chief Scientific Officer & Co-FounderJoshua Soldo has over 25 years of experience in diagnostic technology and product development, with prior leadership roles in R&D and Medical & Scientific Affairs at Roche Diagnostics, DiaSorin, Beckman Coulter, and Anteo Technologies, where he contributed to immunoassay development and commercialization. He holds numerous patents in solid phase chemistry and biomarker testing, and founded Veravas to develop the VeraBIND diagnostic platform for improving biomarker detection in laboratory testing.

Frederick Allen BaumbachNamed on SEC filing

Carroll E. Streetman, Jr.Named on SEC filing

Reported raises · per SEC filings

Form D private placements

$21.7M disclosed across 3 rounds · 2019–2024

▶$20.6MraisedApr 2024 · 138 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Jeremy CooteDirector
James KyleDirector
John ForrestExecutive Officer, Director, Promoter
Luc VanhalExecutive Officer
Will KikerDirector

Offering amount: $26.4M
Amount sold: $20.6M
Proceeds to insiders: $625K
First sale: Mar 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$775KraisedMar 2023 · 12 investors · Other Health Care

Rule 506(c)

Officers, directors & promoters on the filing

John ForrestExecutive Officer

Offering amount: $50M
Amount sold: $775K
Minimum investment: $25K
First sale: Oct 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$375KraisedOct 2019 · 6 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Frederick Allen BaumbachExecutive Officer
John Michael ForrestExecutive Officer, Director, Promoter
Carroll E. Streetman, Jr.Executive Officer

Offering amount: $2M
Amount sold: $375K
Proceeds to insiders: $160K
First sale: Sep 2019
Incorporated: Corporation, Delaware, 2017
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

VeratxVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.

Verana HealthVerana Health aggregates de-identified clinical data from a network of over 20,000 physicians in ophthalmology, urology, and neurology to power real-world evidence, clinical trial enablement, and quality reporting for pharmaceutical companies and healthcare providers using AI and machine learning.

VerastemVerastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients. The company focuses on oncology therapeutics including small molecules and monoclonal antibodies targeting pathways such as RAS, KRAS, and immune modulation.

VerasVeras builds a workforce platform for the long-term and post-acute care industry, handling shift-based scheduling, CMS compliance, and frontline care workforce management. It targets care operators, aiming to reduce labor costs and improve staff retention and quality of care.

Companies working in the same space as Veravas.

In the news

Veravas, Inc. joins national accelerator to advance heart and brain health - Veravasveravas.com

Frequently asked questions

What does Veravas do?: Veravas develops the patented VeraBIND diagnostic platform that reduces interference in laboratory testing to measure hard-to-detect biomarkers, with a current application in blood-based early detection of tau pathology associated with Alzheimer's disease. It provides tests and sample pre-treatment solutions aimed at researchers and diagnostic labs for improved assay sensitivity and biomarker detection.</parameter> <parameter name="founders">[]
Who founded Veravas?: Veravas was founded by John Forrest, Joshua Soldo in 2017.
How much funding has Veravas raised?: Veravas has disclosed $21.7M raised across 3 rounds.
Where is Veravas headquartered?: Veravas is headquartered in Charleston, US.